← Back to Clinical Trials
Recruiting NCT06508801

NCT06508801 Blood Flow Restriction for Optimizing Balance in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06508801
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition Parkinson's Disease and Parkinsonism
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-01-07
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Blood flow restriction trainingInstability Resistance Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-01-07 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being done to understand how reducing blood flow (BRT) during balance-challenging strengthening exercises (instability resistance training, or IRT) can help improve symptoms of Parkinson's disease.

Eligibility Criteria

Inclusion Criteria: 1. Males and females between the ages 40 - 85 with a diagnosis of idiopathic Parkinson's Disease (PD) consistent with the United Kingdom PD society brain bank criteria, 2. in Hoehn and Yahr stage 2-4, 3. a score of ≥23 on the mini-Mental Scale Examination. Exclusion Criteria: 1. History of cardiovascular disease, uncontrolled hypertension (blood pressure ≥140/90 mmHg), orthostatic hypotension, deep-vein thrombosis, varicose veins, or rhabdomyolysis; 2. Ankle branchial index ≤ 0.9 or \> 1.3. 3. History of other neurological disorders affecting the central nervous system such as stroke, multiple sclerosis, tumors, amyotrophic lateral sclerosis or muscle disease such as muscular dystrophy, myopathy. 4. History of uncontrolled diabetes, severe osteoporosis, or cognitive impairment. 5. Body mass index above 40; such individuals are more likely to have poorer muscle function and more pain. 6. Absolute contraindications to exercise as per the American College of Sports Medicine (uncontrolled arrhythmias, third-degree heart block, recent electrocardiogram (EKG) changes, unstable angina, acute myocardial infarction, or acute congestive heart failure 7. Had surgery in the lower extremities within the past 6 months. 8. Pre-menopausal and not on birth control 9. Pregnant or planning to become pregnant within the course of the study 10. Plan to have major surgery within 2 months.

Contact & Investigator

Central Contact

Anjali Sivaramakrishnan, PhD, PT

✉ sivaramakris@uthscsa.edu

📞 210-567-8626

Principal Investigator

Anjali Sivaramakrishnan, PhD, PT

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT06508801 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Parkinson's Disease and Parkinsonism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06508801 currently recruiting?

Yes, NCT06508801 is actively recruiting participants. Contact the research team at sivaramakris@uthscsa.edu for enrollment information.

Where is the NCT06508801 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT06508801 clinical trial?

NCT06508801 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Anjali Sivaramakrishnan, PhD, PT at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology